Novogen Cardiovascular Drug Enters Phase I Clinical Trial
April 02 2008 - 8:00AM
Marketwired
SYDNEY, AUSTRALIA and NEW CANAAN, CT with or without stenting,
or coronary artery bypass surgery.
The processes causing restenosis are complex, but occur as a
direct result of vessel injury during the stenting procedure, local
inflammation and remodelling, together with the same processes of
atherosclerosis that caused the vessel to block initially. NV-27
has been demonstrated to inhibit those processes in vitro via a
variety of mechanisms. Importantly, orally administered NV-27 has
been extremely effective in protecting against restenosis following
endothelial injury in animal studies. NV-27 therefore appears to be
ideally suited as an orally delivered agent to reduce restenosis
following coronary artery stenting.
About restenosis
The coronary arteries supply blood to the heart. Through a
variety of mechanisms including aging, a diet high in fat, smoking
and inadequate exercise, atherosclerosis causes these arteries to
block, resulting in angina (heart pain) or more critically an acute
myocardial infarction (heart attack).
These vessels can be unblocked by a process called angioplasty,
where the vessel is reopened using a balloon inflated inside the
artery. More commonly, a small metal scaffold called a stent can be
inserted to hold the artery open for an extended period.
Unfortunately, the vessel often blocks up again in a process called
'restenosis.'
Depending on the type of stent used, the type of lesion and
whether or not the patient is a diabetic and/or a smoker,
restenosis may occur in up to 50% of procedures. The stent then
needs to be replaced with another. If the disease is very severe, a
patient may undergo bypass surgery where the coronary arteries are
replaced with veins from other parts of the body. Again, restenosis
can occur, requiring the surgery to be repeated.
Though the addition of immunosuppressive or anti-proliferative
agents such as coating on stents (so called drug-eluting stents)
have reduced the occurrence of restenosis, it still remains a
significant clinical problem, the results of which can be
catastrophic.
About Novogen Limited:
Novogen Limited (ASX: NRT) (NASDAQ: NVGN) is an Australian
biotechnology company that has patented isoflavone technology for
the treatment and prevention of degenerative diseases and
disorders. Over the past ten years, Novogen has conducted the
largest and most comprehensive isoflavone clinical testing programs
in the world. Novogen is involved in drug discovery and product
development for disorders that are commonly associated with aging
and coordinates an international clinical research and development
program with external collaborators, hospitals and universities.
For more information, visit www.novogen.com.
Under U.S. law, a new drug cannot be marketed until it has been
investigated in clinical trials and approved by the FDA as being
safe and effective for the intended use. Statements included in
this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product
candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties in clinical trial results; our inability
to maintain or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products; competitive
factors; our inability to protect our patents or proprietary rights
and obtain necessary rights to third party patents and intellectual
property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to
gain market acceptance; our inability to obtain any additional
required financing; technological changes; government regulation;
changes in industry practice; and one-time events. We do not intend
to update any of these factors or to publicly announce the results
of any revisions to these forward-looking statements.
Add to Digg Bookmark with del.icio.us Add to Newsvine
For further information: Professor Alan Husband Research
Director Novogen Limited TEL 011 2 9878 0088 http://www.novogen.com
WHITECOAT STRATEGIES CONTACT: David Sheon TEL 202 470-2880
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024